Bionano Genomics (BNGO) Total Current Liabilities (2017 - 2026)

Bionano Genomics has reported Total Current Liabilities for 10 years, with the latest figure at $21.2 million in Q1 2026.

• Quarterly Total Current Liabilities fell 19.62% year-over-year to $21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.2 million (down 19.62% YoY) and the FY2025 annual result came in at $22.9 million, down 38.57% from the prior year.
• Total Current Liabilities retreated to $21.2 million in Q1 2026 per BNGO's latest filing, from $22.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $100.0 million in Q4 2023 and troughed at $18.7 million in Q1 2022.
• A 5-year average of $36.0 million and a median of $33.5 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities jumped 178.75% in 2023, then sank 62.67% in 2024.
• Over 5 years, Total Current Liabilities stood at $35.9 million in 2022, then surged by 178.75% to $100.0 million in 2023, then tumbled by 62.67% to $37.3 million in 2024, then plunged by 38.57% to $22.9 million in 2025, then slipped by 7.47% to $21.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $21.2 million, $22.9 million, and $23.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.